Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Martin Dyroff"'
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 12, Pp 2888-2898 (2022)
Abstract The pharmacometric analysis of the double‐blind, randomized, phase II study (NCT02975349) investigating the safety and efficacy of evobrutinib, explored exposure–response relationships and suitable dosing regimens of evobrutinib for rela
Externí odkaz:
https://doaj.org/article/1574bc86c94149c2ace8e09bd96f649c
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 12, Pp 2899-2908 (2022)
Abstract Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown therapeutic potential in relapsing multiple sclerosis. This analysis aimed to develop pharmacokinetic (PK) and pharmacodynamic (PD; BTK occupancy [BTKO]) models of evobrutini
Externí odkaz:
https://doaj.org/article/64656ea9310f4b0f898d8fa0c197deb8
Autor:
Holger Scheible, Martin Dyroff, Annick Seithel‐Keuth, Eleanor Harrison‐Moench, Nadra Mammasse, Andreas Port, Angelika Bachmann, Jennifer Dong, Jan Jaap vanLier, William Tracewell, David Mitchell
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2420-2430 (2021)
Abstract The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indi
Externí odkaz:
https://doaj.org/article/489421b638da46dbad0cbcea83c71c6e
Autor:
Eleanor Harrison-Moench, Jan J. van Lier, Jennifer Dong, Angelika Bachmann, David Mitchell, Andreas Port, Nadra Mammasse, Annick Seithel-Keuth, Martin Dyroff, William Tracewell, Holger Scheible
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2420-2430 (2021)
Clinical and Translational Science
Clinical and Translational Science
The highly selective, covalent Bruton’s tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indicated tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::918d725112442079a32e919b8e766712
https://doi.org/10.1111/cts.13108
https://doi.org/10.1111/cts.13108
Autor:
Wojciech Jurczak, Simon Rule, David L. Tucker, Monika Długosz-Danecka, Pier Luigi Zinzani, Jürgen Scheele, John G. Gribben, Barbara Sarholz, Martin Dyroff, William Townsend
Publikováno v:
Leukemialymphoma. 62(10)
M7583 is a potent, highly selective, covalent BTK inhibitor in development. In this phase I, first-in-human, open label, multicenter dose-escalation trial, M7583 was given at 80 mg (threedays)/160 mg (full 28-day cycle), then 300 mg/day, 600 mg/day,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e09ff224565679b0ba9929968b415194
https://pubmed.ncbi.nlm.nih.gov/33896333
https://pubmed.ncbi.nlm.nih.gov/33896333
Autor:
Matthew Mandel, Karolina Piasecka-Stryczynska, David Mitchell, Xavier Montalban, Emily Martin, Carolina Cunha, Martin Dyroff, Konrad Rejdak, Yann Hyvert, Kristina Holmberg
Publikováno v:
Multiple Sclerosis and Related Disorders. 51:103001
Background Evobrutinib, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, demonstrated a low annualized relapse rate (75mg twice-daily: 0.11, 95%CI 0.04–0.25) in a phase 2 randomized controlled trial in patients with relapsing multiple s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dfe0db6d9472acd6f26801e302c06f23
https://doi.org/10.1016/j.msard.2021.103001
https://doi.org/10.1016/j.msard.2021.103001
Autor:
Christian Lüpfert, Martin Dyroff, Oliver von Richter, Dieter Gallemann, Samer El Bawab, Hugues Dolgos, Stefan Hecht, Andreas Johne, Don Jung
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Evofosfamide is a cytotoxic small-molecule prodrug preferentially activated under hypoxic conditions. The cytotoxicity of evofosfamide impacted the generation of in vitro drug-drug interaction (DDI) data, especially in vitro induction results. Theref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1283e1c19491230198345391122408c
https://pubmed.ncbi.nlm.nih.gov/30311747
https://pubmed.ncbi.nlm.nih.gov/30311747
Publikováno v:
Journal of Chromatography B: Biomedical Sciences and Applications. 695:299-307
A liquid chromatography–atmospheric pressure chemical ionization tandem mass spectrometry (LC–APCI-MS–MS) method is described for the determination of a thromboxane receptor antagonist (4 Z )-6-((2 S ,4 S ,5 R )-2-(1-(2-cyano-4-methylphenoxy)-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0f4383e68ec6a3220c10d42c93c7a2a
https://doi.org/10.1016/s0378-4347(97)00199-0
https://doi.org/10.1016/s0378-4347(97)00199-0
Autor:
C.J. Ohnmacht, Howard S. Shapiro, Frederick J. Brown, C.A. Frank, Christopher Ceccarelli, R. W. Smith, Keith Hopkinson Gibson, Kathleen L. Neilson, Keith Russell, Paul James Warwick, Janet M. Forst, James Hulsizer, Joseph James Lewis, Martin Dyroff, Tracy J. Halterman, Diane Amy Trainor, Jack H. Li, James Roy Empfield, Christopher L. Yochim, M. Kirkland, Sen T. Kau, T. Grant, Margaret M. Lin, Robert Joseph Harris, Burton B. Howe, Alexa L. Chun, S. Trivedi, Mclaren Frances Marie, Stuart M. Silverman, Brian Bernard Masek, Daniel Ray Mayhugh
Publikováno v:
Journal of Medicinal Chemistry. 39:4592-4601
A subset of antiandrogen compounds, the N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides 1, were found to activate ATP sensitive potassium channels (KATP) and represent a new class of potassium channel openers (PCOs). A structure-activity relati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da246722b658b8996532067701cea520
https://doi.org/10.1021/jm960365n
https://doi.org/10.1021/jm960365n
Publikováno v:
Breast Cancer Research and Treatment. 30:103-111
Arimidex® is a potent and selective aromatase inhibitor undergoing evaluation as a treatment for postmenopausal women with advanced breast cancer. Studies to determine the pharmacology of Arimidex were conducted in both animals and humans. In animal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99761c60ca2b60cbf47f3ef5028d74d8
https://doi.org/10.1007/bf00682745
https://doi.org/10.1007/bf00682745